Evidence map›Paper›PMID 30556200›Full record

ArticleHead & neck2019

PI3-kinase pathway biomarkers in oral cancer and tumor immune cells.

Mohammad Y Ibrahim, Maria I Nunez, Nusrat Harun, J Jack Lee, Adel K El-Naggar, Renata Ferrarotto, Ignacio Wistuba, Jeffrey Myers, Bonnie S Glisson, William N William

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mohammad Y IbrahimSeton Hall University College of Arts and Sciences, Department of Internal Medicine at St. Francis Medical Center.
Maria I NunezThe University of Texas MD Anderson Cancer Center, Department of Pathology.
Nusrat HarunThe University of Texas MD Anderson Cancer Center, Department of Biostatistics.
J Jack LeeThe University of Texas MD Anderson Cancer Center, Department of Biostatistics.
Adel K El-NaggarThe University of Texas MD Anderson Cancer Center, Department of Pathology.
Renata FerrarottoThe University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology.
Ignacio WistubaThe University of Texas MD Anderson Cancer Center, Department of Pathology.
Jeffrey MyersThe University of Texas MD Anderson Cancer Center, Head and Neck Surgery, Houston, TX.
Bonnie S GlissonThe University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology.
William N WilliamThe University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology.
The University of Texas MD Anderson Cancer Center · USSeton Hall University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA097007
6 · The paper itself

Abstract

backgroundThis study investigated the hypothesis that phosphoinositide 3-kinase (PI3-kinase) pathway dysregulation in either head and neck cancer cells and/or tumor infiltrating immune cells would influence outcomes of patients with surgically treated oral tongue squamous cell carcinomas (SCC).

methodsWe constructed tissue microarrays containing 123 oral tongue SCC samples and performed immunohistochemistry using antibodies against 7 PI3-kinase pathway markers: phosphatase and tensin homolog (PTEN), Akt, p-Akt, mammalian target of rapamycin (mTOR), phosphorylated-mammalian target of rapamycin (p-mTOR), survivin, and Ki-67). Expression levels in cancer cells or tumor infiltrating immune cells were correlated with outcomes.

resultsHigher levels of PTEN expression in immune cells were significantly associated with improved recurrence-free survival (heart rate (HR) = 0.45, 95% confidence interval (CI) 0.23-0.90, P = .03), and overall survival (HR = 0.34, 95% CI 0.15-0.76, P = .01) on univariate and multicovariate models.

conclusionsWe identified a novel, negative prognostic role of PI3-kinase activation (as determined by PTEN loss) in oral SCC infiltrating immune cells. These findings could be relevant for clinical development of PI-3 kinase inhibitors for this disease.

Indexed as

BiomarkersCarcinoma, Squamous CellFemaleHumansLymphocytesMacrophagesMaleMiddle AgedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseRetrospective StudiesSignal TransductionSurvival RateSurvivinTongue NeoplasmsBiomarkersBIRC5 protein, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanSurvivinTOR Serine-Threonine Kinasesimmunologyoral squamous cell carcinomasphosphatase and tensin homolog (PTEN)phosphoinositide 3-kinase pathway (PI3-kinase pathway)tumor infiltrating immune cells

Identifiers

PMID30556200
PMCPMC6382518
OpenAlexW2903876545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.